



Invanz[®] (ertapenem) – First-time generic

- On June 26, 2018, [Aurobindo announced](#) the FDA approval of an **AP-rated** generic version of Merck's [Invanz \(ertapenem\)](#) injection, for the treatment of adult patients and pediatric patients (3 months of age and older) with certain moderate to severe infections caused by susceptible isolates of designated microorganisms; and for the prevention of surgical site infection following elective colorectal surgery.
 - Aurobindo's generic Invanz will launch in July 2018.
- The approved product has an estimated market size of \$387 million for the 12 months ending in April 2018 according to IQVIA.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.